An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus

An Observational Study of Risk Factors Influencing Glycemic Status and Optimized Treatment on Post-chronic Pancreatitis Diabetes Mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05764629

Enrollment

324

Registered

2023-03-10

Start date

2021-09-01

Completion date

2030-12-31

Last updated

2023-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pancreatitis, Diabetes Mellitus

Brief summary

To explore the risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus (PPDM-C).

Detailed description

The present study was an observational study aimed to explore risk factors influencing glycemic status, optimized treatment, and prognosis of post-chronic pancreatitis diabetes mellitus. The observation items included clinical characteristics, blood glucose control and incidence of complications of PPDM-C.

Interventions

DIAGNOSTIC_TESTblood test

Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.

DRUGpharmacologic approaches to glycemic treatment

documenting the change of glycemic treatment during the follow-up period

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. patients with diagnosis of chronic pancreatitis and diabetes mellitus. 2. participants with painless chronic pancreatitis were diagnosed with diabetes within 2 years of the diagnosis of chronic pancreatitis. 3. participants with painful chronic pancreatitis were diagnosed with diabetes after the first attack of chronic pancreatitis.

Exclusion criteria

1. participants with suspected malignant tumors of the pancreas or other sites of body, or participants in the terminal stage of severe disease 2. serious mental illness, lesion of liver or kidney, pregnancy, breast-feeding or planning pregnancy 3. definitely diagnosed type 1 diabetes, type 2 diabetes, or other metabolic diseases that affect blood glucose 4. autoimmune pancreatitis 5. Scarcity of information related to HbA1c 6. death or loss of follow-up during follow-up

Design outcomes

Primary

Measure	Time frame	Description
Hemoglobin A1c (HbA1c)	through study completion, an average of 1 year	measure the control of blood glucose of every 3 months

Secondary

Measure	Time frame	Description
Adverse events	through study completion, an average of 1 year	Incidence and frequency (number of events) of adverse events (%) such as hypoglycemia, cardiovascular disease, etc.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026